MUManon G. Den Uil

Manon G. Den Uil

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manon G. Den Uil has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost-effectiveness of pre-emptive pharmacogenetic testing: An umbrella review

    by Taichi Ochi, Manon G. Den Uil, Greta Piazza, Geert W. J. Frederix, Eelko Hak, Vera H. M. Deneer, Talitha L. Feenstra

    Background: Consortia have been established and published pharmacogenetic-specific guidelines with pharmacotherapeutic recommendations. While these consortia and their guidance addressed important information gaps, implementation barriers, including determining the cost-effectiveness for further implementation in healthcare practice, remain unaddressed. Methods: The authors systematically searched PubMed, EMBASE, and Web of Science from inception to March 2023 for systematic reviews of pharmacoeconomic evaluations of PGx studies. A second search was conducted in October 2025. The studies from the databases were imported into Rayyan for screening the title and abstract, based on the inclusion and exclusion criteria. The umbrella review was conducted in adherence to the proposal registered in PROSPERO (CRD42023408535). The quality of eligible systematic reviews was assessed by the AMSTAR-2 checklist. Results: From the initial screening of the three databases, title and abstract screening, and full paper readings, 17 systematic reviews were included for the umbrella review. The evidence points to the fact that with an increasing number of evaluations, the evidence for the cost-effectiveness of PGx testing was increasing over the years. From the included reviews, data from 211 unique evaluation studies were extracted. 150 (71.1%) studies reported that PGx testing was cost-effective. The most frequently used type of economic evaluation was cost-utility analysis (n = 78). Most economic evaluations investigated the pharmacogene CYP2C19 (n = 46), followed closely by CYP2C9/VKORC1 (n = 28). Conclusions: The number of economic evaluations demonstrating cost-effectiveness of PGx testing has increased over the years. However, the majority of these evaluations were conducted in a small number of countries. When interpreting findings for different countries, the evaluations need to be adjusted on a case-by-case basis for applicability.


  • Open Access

    Ketoproof? A systematic classification of pharmaceutical excipients for ketogenic diet therapy

    by Samir El Abdouni, Manon G. Den Uil, Zikrullah Kafa, Tatiana Soares Ribeiro, Elles J. T. M. van der Louw, Elisabeth J. Ruijgrok, A. Laura Nijstad

    Introduction: Ketogenic diet therapy (KDT) is an evidence-based treatment for refractory epilepsy, particularly in children. Strict adherence to carbohydrate restriction is essential to maintain ketosis, yet many medications contain excipients that can disrupt this balance. Pharmacists play a crucial role in evaluating and adjusting medication regimens for patients on KDT, but limited transparency regarding excipient content often makes this process inefficient and inconsistent. Although some regional databases exist, no systematic and comprehensive resources have been developed for broader use. Aim: This study aimed to systematically classify pharmaceutical excipients and label all medications marketed in the Netherlands according to their compatibility with KDT (“Ketoproof” status) using a transparent, reproducible framework that can serve as the foundation for safer prescribing and international standardization. Method: A retrospective cross-sectional database analysis was conducted using data from the Dutch G-Standaard (June 2023–March 2024), a national pharmaceutical reference database used in the Netherlands. All excipients authorized in medications marketed in the Netherlands were extracted and classified based on chemical composition, metabolic fate, and administration route. Excipients were assigned a Ketoproof status through a structured decision flowchart, expert consensus, and quality control review. Finally, pharmaceutical products were labeled by cross-referencing their excipient profiles against the classified dataset. Results: A total of 1047 excipients were identified. Of these, 778 (74%) were successfully classified: 590 (56%) as Ketoproof and 188 (18%) as non-Ketoproof. The remaining 269 (26%) were unclassified. Excipients requiring expert consensus included polyols and sugar alcohols, organic acids, and coloring and flavoring agents, which were carefully assessed for clinical relevance. Among 28,721 pharmaceutical products analyzed, 41% (n = 11,781) were labeled as Ketoproof. The full dataset was integrated into KetoMed, a web-based tool designed to support healthcare professionals in reviewing medications for patients on KDT. Conclusion: This study presents the first systematic classification of pharmaceutical excipients for KDT compatibility. The transparent, evidence-informed framework enables structured labeling of medications and supports safer prescribing for patients undergoing KDT. Broader adoption and international collaboration are recommended to establish consensus on excipient classification, enhance regulatory transparency, and integrate Ketoproof labeling into clinical decision-support systems to optimize ketogenic therapy management.